![Spero Therapeutics Inc](/common/images/company/N_SPRO.png)
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is de... Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. Show more
CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.Β (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
U.S. index futures are virtually flat in pre-market trading this Wednesday, with Wall Street awaiting April’s consumer price index data. At 7:18 AM, Dow Jones futures (DOWI:DJI) were up 3...
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.Β (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.Β (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.Β (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.02 | -1.40845070423 | 1.42 | 1.53 | 1.39 | 121906 | 1.46627912 | CS |
4 | 0.06 | 4.4776119403 | 1.34 | 1.53 | 1.27 | 100279 | 1.38342934 | CS |
12 | -0.06 | -4.1095890411 | 1.46 | 1.72 | 1.25 | 149211 | 1.45032925 | CS |
26 | 0 | 0 | 1.4 | 1.89 | 1.25 | 237966 | 1.58925741 | CS |
52 | -0.04 | -2.77777777778 | 1.44 | 1.89 | 0.99 | 242466 | 1.4663655 | CS |
156 | -13.65 | -90.6976744186 | 15.05 | 19.87 | 0.6801 | 964057 | 2.17743162 | CS |
260 | -8.6 | -86 | 10 | 23.639 | 0.6801 | 644741 | 3.50569603 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.